Algeria has recently introduced tax incentives to attract foreign investment, particularly in the pharmaceutical sector, according to Pharmaceutical Executive. The move aims to modernize the healthcare system and reduce dependency on imports by encouraging domestic production.
The Algerian government has approved a series of tax exemptions for overseas investors setting up operations in the country. These include full exemption from corporate tax for the first five years of activity, followed by a 50% reduction for the next five years. Import duties on raw materials and equipment for pharmaceutical manufacturing are also being waived. The National Agency for Investment Development (ANDI) is overseeing the implementation of these measures.
Foreign investors will be allowed to repatriate profits without restrictions, which addresses a long-standing concern among the diaspora business community. According to Pharmaceutical Executive, the reforms target sectors deemed strategically important, with healthcare production—including pharmaceuticals—at the forefront.
The policy comes as Algeria seeks to bolster local manufacturing. The country currently imports around 70% of its pharmaceutical needs, spending billions of dollars annually on foreign-made medicines. This reliance has been highlighted by recent supply chain disruptions, including those caused by the COVID-19 pandemic. By incentivizing local production, the government aims to reduce import costs and create jobs.
Entrepreneurs in the pharmaceutical industry are encouraged to explore partnerships with Algerian firms. The government has pledged to streamline licensing and reduce bureaucratic hurdles for foreign investors. ANDI has established dedicated support units to assist overseas businesses in navigating the regulatory landscape.
The tax incentives may also benefit Algerian entrepreneurs returning from the diaspora. Many have experience in international pharmaceutical markets and could leverage these policies to launch or expand ventures in Algeria. The government’s focus on repatriation flexibility signals openness to diaspora capital and expertise.
Pharmaceutical Executive notes that these measures reflect broader economic reforms. Earlier this year, Algeria adjusted its 2020 finance law to include additional fiscal advantages for investors in priority sectors. The pharmaceutical industry has been designated a priority, receiving special attention due to its role in public health and economic resilience.
For entrepreneurs considering entry into the Algerian market, the new incentives provide a tangible opportunity. The absence of import duties and the ability to repatriate earnings could significantly lower operational costs and improve margins. However, the effectiveness of these measures will depend on their implementation and the continued stability of Algeria’s regulatory environment.
Key takeaway for entrepreneurs
The Algerian government’s new tax breaks offer foreign investors up to 10 years of reduced corporate tax and duty-free imports in pharmaceuticals. Entrepreneurs in the sector can now repatriate profits freely, while diaspora investors benefit from streamlined regulations. Success will hinge on collaboration with local partners and clarity in policy application.
💡 Starting a business in Algeria? GlobalStart guides you step by step: procedures, real costs, company forms (SARL, EURL, SPA) and CNRC registration.